USFDA completes audit of Shilpa Medicare's Jadcherla facility

27 Jul 2016 Evaluate

USFDA has completed audit of Shilpa Medicare’s Jadcherla facility. The company has received ‘without 483’ for its SEZ formulations facility situated at Jadcherla near Hyderabad from the United States Food & Drug Administration (USFDA). USFDA’s 483 is a form issued to a company or management at the conclusion of an inspection when an investigator(s) has observed any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts. The USFDA had conducted audit from July 18 to 26.

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.

Shilpa Medicare Share Price

919.00 -16.80 (-1.80%)
22-Nov-2024 12:55 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1783.25
Dr. Reddys Lab 1210.45
Cipla 1487.00
Lupin 2056.70
Zydus Lifesciences 946.50
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.